A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results
Results provide important building blocks for stimuli development and highlight the need for a novel gene editing lexicon. In the next phase, language stimuli will be tested with LEEs and haematologists to better understand audience preferences and help shape the final lexicon.
Authors
- William McKeown (ORCID: https://orcid.org/0009-0006-1916-041X)
- Cedric R.J.R. Hermans (ORCID: https://orcid.org/0000-0001-5429-8437)
- Steven W. Pipe (ORCID: https://orcid.org/0000-0003-2558-2089)
- Mark A. Kay (ORCID: https://orcid.org/0000-0002-2799-2615)
- Courtney D. Thornburg (ORCID: https://orcid.org/0000-0002-5665-8958)
- Craig M. Kessler (ORCID: https://orcid.org/0000-0003-0599-5724)
- Paul Smith (ORCID: https://orcid.org/0000-0002-7850-8440)
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Leonard A. Valentino (ORCID: https://orcid.org/0000-0002-7927-6418)
- Carmen Unzu (ORCID: https://orcid.org/0000-0002-1582-7196)
- Kate Khair (ORCID: https://orcid.org/0000-0003-2001-5958)
- Glenn F. Pierce (ORCID: https://orcid.org/0000-0002-3310-328X)
- Wolfgang Miesbach (ORCID: https://orcid.org/0000-0002-4506-0061)
- Micheala Jones
- Katarina Starcevic
- Monisha Pillai
- Megan Chiao
- Ilia Antonino
Institutions
- Goethe University Frankfurt (DE)
- Cliniques Universitaires Saint-Luc (BE)
- Georgetown University (US)
- Regeneron (United States) (US)
- University of Milan (IT)
- Canadian Hemophilia Society (CA)
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- Michigan Medicine (US)
- Intellia Therapeutics (United States) (US)
- University Hospital Frankfurt (DE)
- Rush University (US)
- Universidad de Navarra (ES)
- Stanford University (US)
Publication Details
- Journal
- Haemophilia
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1111/hae.15108
- Citations
- 5
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Regeneron Pharmaceuticals